Advertisement
Advertisement
U.S. Markets open in 8 hrs 41 mins
Advertisement
Advertisement
Advertisement
Advertisement

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.33+0.11 (+1.19%)
At close: 04:00PM EST
9.33 0.00 (0.00%)
After hours: 07:55PM EST
Advertisement
Sign in to post a message.
  • A
    Anonymous
    This is a pretty insane valuation considering they have 200M in cash and a 60% stake in Calyxt . $ALLO should just buy them for peanuts and have instant access to state of the art manufacturing facilities for CAR-T.
  • S
    Sweet
    Been holding for about 2+ years. Was going to sell when it doubled, but thought it could go higher at the time. Held. IMO It's gonna be in the dumps until actual positive earnings happen. (some) can't lose money forever. Also depending on public backlash on various aspects of 'gene therapy' some gene editing stocks could have some harsh restrictions on research in the future. This is what happens when the 'big boys' force a non-effective untested gene therapy on the public and ruin more focused thoroughly tested gene therapies that actually could help *real* terminal illness. Luckily the FDA and CDC are still completely corrupt (other then the droves that are resigning or quitting) so it can be the wild west still in terms of gene therapy.
  • P
    Peter
    Reason for huge drop in stock price after hours Thursday is that FDA has put a hold on clinical trials with another US company working on a similar therapy as CLLS:

    Allogene Therapeutics Inc. ALLO, +1.71% shares plunged in the extended session Thursday after the biotech drug developer said the Food and Drug Administration placed a hold on the company’s cancer drug clinical trials. Allogene shares, which had closed up 1.7% at $24.38 in the regular session, plunged as much as 40% after hours following a brief halt. Allogene said a single report of a “chromosomal abnormality” in a stage IV follicular lymphoma patient treated with the company’s ALLO-501A CAR T prompted the FDA put a hold on the drug’s study until an investigation is completed. “The company expects to provide additional updates in the coming weeks following consultation with the FDA,” Allogene said in a statement. “The FDA continues to actively review the end of Phase 1 materials submitted in anticipation for an ALLO-501A pivotal Phase 2 trial.”
  • A
    Anonymous
    Needs the Allo lift to happen - nothing as of yet to say either way or how long it will take. My selfish wish is for management to unload their stake in Calyxt, which is assigned no value by wall street. Calyxt seems to have nice mission statement now, no need for CLLS to be involved anymore. Take the cash and stop diluting the stock for awhile.
    Bullish
  • A
    Anonymous
    WOW what an over reaction here. ALLO and TALEN are not finished because of one incident which no one knows anything about yet. CLLS in particular has 200M+ in cash and 50M+ stake in calyxt and still eligible to receive billions in milestone payments. At 4XXM market cap, seems like a no brainer once their friends at Allogene sort out what is going on with the FDA.
  • A
    Anonymous
    Funny - never moved when the same analyst gave huge a 39.00 price target last year, but of course it tanks when he moves it lower. Analyst are manipulators, price targets are not for the average investor.
  • L
    Leonid
    Was watching CLLS for a while and finally pulled the trigger today and bought some shares. Today is a compassionate with ALLO fall. Should be corrected in a week.
    Bullish
  • P
    Peter
    ARK Funds ( Cathie Woods) may be dumping large chunks of stock in after hours?
    Time to load up and backup the truck ?
  • b
    bligh
    I heard about CLLS the other day on (http://Stocks-tracker.com). It’s looking like an interesting play.
  • A
    Anonymous
    Surprised this fell so much. It doesn't really seem all that justified. All retail revised down PTs for ALLO, all down but all still significantly higher than current SP. Meanwhile, Baird changes theirs from 39-->10 on CLLS, what gives? Screams give me cheap shares. CLLS has plenty of cash and a majority holding in an unrelated holding, CLXT, that I suspect they will sell off soon for even more cash. Curious for others thoughts, but these are mine. I just hope ALLO gets clarity in <4-6 weeks timeframe.
    Bullish
  • O
    Octavius
    just a poster compsny
  • P
    Peter
    Now we know why Cathie Wood and ARK Funds have been dumping all their CLLS shares over the last month. They must have had a clue on what is going on..?

    "Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
    Published on April 03, 2018 in New York, NY (USA) "
  • J
    James
    Cytovia Therapeutics, a biopharma developing NK and CAR-NK cells derived from iPSCs, and Cellectis are now collaborating to develop TALEN gene-edited versions. Cellectis will receive up to $760M of milestone payments for the first five products and single-digit royalty payments on the net sales of all partnered products.

    Cellectis will also receive an equity stake of $15M in Cytovia stock, or an upfront cash payment of $15M if certain conditions are not met by the end of this year, as well as an option to invest in future financing rounds. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing tech, enabling them to modify NK cells addressing multiple gene targets for therapeutic use in at least several indications.
  • A
    Anonymous
    very voalitile stock, but don't sleep on what they are going to accomplish in the next 5 years. This has a real chance to reach 100.00/sh, no joke. Just my opinion. From just a few partners they already have, they have many more - this was also pulled from the CC - "As a reminder, we are eligible to receive $4 billion in disclosed development and sales milestones, plus royalty on sales from our partner, Allogene, Servier and Cytovia". They also own calyxt which they could prune for a handsome reward when the time is right. GLTA.
    Bullish
  • j
    jimmy
    This stock is not getting the respect it should get when you see the activity with NTLA, EDIT, BEAM, CRSP and the moves they each are making. Again, is it because they are a European company and not seeing a lot of interest from domestic retail and institutional investors? This could be a sleeper. Thoughts. God Bless and stay well.
  • D
    Donna
    PR says milestone payments could be 2.3 BILLION, that is $77/share not including drug royalties !
  • J
    J. MichaelS
    Buyout Coming?
  • S
    Scott
    Market not liking the follow on offering of $100 million. Opportunity or warning?
  • J
    James
    Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A ... | February 18, 2020
    Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A ... | February 18, 2020
    www.marketscreener.com
  • J
    J. MichaelS
    Well, we should find out in the next earning report how much CLLS is receiving in progress payments for a new IND from ALLO.
    Then in the 3rd quarter, what the progress payment is when the UCART19 product goes in a Phase II/III phase with ALLO.
    CLLS should have a relatively steady stream of revenue from this point forward.
    I am still a little puzzled why the duplication of manufacturing in the US. ALLO is building mfg in California and CLLS in Raleigh, NC.
    Anyone have any thoughts?
Advertisement
Advertisement